A comprehensive portal site for
Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Satoshi Fukushima

Globis Capital Partners & Co.

He graduated from the Faculty of Economics, University of Tokyo. He was involved in investment activities in reformed fields of existing industries, including digital health, at Globis Capital Partners & Co. (GCP). He served as an outside director of several companies, including Medley, Inc., Kakehashi Inc., and Yoriso. Co. Ltd., and provided support to their management personnel mainly in strategy formulation, development of the organization, and finance. In addition to investigation activities, he provided support for fund structuring and open innovations provided by large companies in healthcare fields.

Before joining GCP, he was serving as an M&A advisor mainly in the technology, media, and telecommunication fields and worked on financing at the general headquarters of German Securities Finance Corporation.

Yoshinori Shinoki

He graduated from the Department of Biopharmaceutical Sciences, Kyoto Pharmaceutical University, and is a licensed pharmacist. At Sawai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K., after taking charge of clinical development, SOP/training, sales planning, management planning office, etc., he acquired experience in planning and implementing various clinical development plans as a project leader for newly developed items in the project management department. In addition, he was involved in formulating a drug price negotiation strategy, post-marketing clinical studies and post-marketing surveillance, and market planning. After that, he launched the clinical development department at Global CRO. Since 2015 when he took his current position, he has supported the planning of the clinical development of development items for small and biological products, as well as negotiating with regulatory authorities. Recently, in addition to medicines, he also supports clinical development strategies of medical devices and the products of regenerative medicine (gene therapy products and cell/tissue processed products) and planning.

Jun Utsumi

CEO, TIR Research Consulting, LLC. and Senior Advisor, Japanese Foundation for Cancer Research

He graduated from the Graduate School of Veterinary Medicine, Hokkaido University. He has a Doctor of Science degree and an MBA; he is a professional engineer (biotechnology), PMRJ-certified regulatory science expert, and veterinarian (DVM). He was in charge of pharmaceutical research and clinical development at Toray Industries, Inc., and successfully developed a novel antipruritus drug (received the Pharmaceutical Society of Japan Award for Drug Research and Development and the Annual Okochi Memorial Technology Prize). After the business career, he engaged in services for collaboration between industry and academia at Hokkaido University and Kyoto University (professor). Then he consecutively held positions as an expert consultant on pharmaceutical affairs strategy in the Pharmaceuticals and Medical Devices Agency (PMDA) and a senior consultant for intellectual property at the Japan Agency for Medical Research and Development (AMED). Based on more than 30 years of experience in the areas of industry, government, and academia, he established a consulting company in 2018. He is providing commercialization strategies in which the essential three factors of medical R & D—technology (T), intellectual property (I) and pharmaceutical affairs (R)—are integrated. He wrote and published “A Guide to Integrated Strategy in Drug Discovery” (Nanzando Co., 2015).

Yusuke Shinozawa

Head of the Investment and Fostering Research Center, Real Tech Fund (Leave a Nest Co., Ltd.)

He graduated with a master's degree in agriculture from the Graduate School of Agricultural and Life Sciences, University of Tokyo. After working at a PR firm, in 2009, he joined Leave a Nest Co., Ltd. In the same year, he launched a Silicon Valley training project for graduate students, which was the first overseas project for Leave a Nest Co., Ltd. In 2012, he also established a media development project, and from 2013, he established the seed acceleration project Tech Planter. He became growth manager at the Real Tech Fund in 2015, where he limited his target fields to biotechnology and marine fields, and he offered business support in these fields. In 2018, he became manager of the Frontier Development Division. He is doing his activities with “starting business operation” as his theme, not “starting a business.”

Hidehiro Ando

Representative, Andy Pharma Partners

He graduated from the Department of Veterinary Medical Science, Faculty of Agriculture, University of Tokyo. He joined Tanabe Pharma Corporation (present Mitsubishi Tanabe Pharma Corporation). After being assigned to the research department of pharmacokinetics, he was involved in partnership-related business of international development department, research and development planning department, etc., including establishment of a joint venture with overseas companies. Subsequently, he worked in the technology transfer department of RIKEN (Institute of Physical and Chemical Research), a regenerative medicine venture, Bayer Yakuhin, a drug discovery venture, and he established a personal office. He has engaged in business development and licensing work for about 35 years, and now, based on his experience and networks, he is supporting business development activities, such as licensing agreements and joint research of domestic and foreign pharmaceutical companies/ventures. He provides comprehensive support services ranging from looking for appropriate partners, preparing the draft of contract outline, contract negotiation, and alliance management with partners after the partnership agreement. Especially, based on experience of practicing on both sides of venture and pharmaceutical companies, he keeps in mind providing informative advice and proposals for specific action plans.